Drybench Patent.
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE, NDA 022044
The patents and exclusivities FDA's Orange Book lists for NDA 022044 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 24 Nov 2026 to 21 Jan 2029, each by its own rule; no one date stands for this product.
- Earliest listed date
- 24 Nov 2026US 7,326,708, substance and product and use patentRule R1 · Products 001, 002 · patent.txt lines 966, 970
- Latest listed date
- 21 Jan 2029US 8,414,921 with pediatric exclusivity, as listedRule R2 · Products 001, 002 · patent.txt lines 967, 971
- Latest substance patent
- 24 May 2027US 7,326,708 with pediatric exclusivity, as listedRule R2 · Products 001, 002 · patent.txt lines 965, 969
- Latest listed patent
- 21 Jan 2029US 8,414,921 with pediatric exclusivity, as listedRule R2 · Products 001, 002 · patent.txt lines 967, 971
- Latest exclusivity
- None listed
4 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 022044, as listed. The sections below name products by these numbers.
Product 001 · JANUMET
- Dosage form; route
- TABLET;ORAL
- Strength
- 500MG;EQ 50MG BASE
- Approval date as listed
- 30 Mar 2007
- Type as listed
- RX
- Applicant as listed
- MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
Product 002 · JANUMET
- Dosage form; route
- TABLET;ORAL
- Strength
- 1GM;EQ 50MG BASE
- Approval date as listed
- 30 Mar 2007
- Type as listed
- RX
- Applicant as listed
- MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
4 entries from 8 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 7,326,708, substance and product and use patent
patent.txt lines 966, 970- Expiry as listed
- 24 Nov 2026
- Rule
- R1
- Flags
- substance · product · use code U-802
- Product numbers
- 001, 002
US 7,326,708 with pediatric exclusivity, as listed
patent.txt lines 965, 969- Expiry as listed
- 24 May 2027
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,414,921, product and use patent
patent.txt lines 968, 972- Expiry as listed
- 21 Jul 2028
- Rule
- R1
- Flags
- product · use code U-1036
- Product numbers
- 001, 002
US 8,414,921 with pediatric exclusivity, as listed
patent.txt lines 967, 971- Expiry as listed
- 21 Jan 2029
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
Listed exclusivities
Each exclusivity FDA lists for NDA 022044, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 022044.
Paragraph IV list rows giving NDA 022044
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 022044, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 022044
Sitagliptin Phosphate and Metformin Hydrochloride · Tablets · 50 mg/500 mg and 50 mg/1000 mg
RLD/NDA as listed: Janumet 22044- First PIV submission
- 18 Oct 2010
- ANDAs
- 5
- 180-day status
- Eligible
- Decision posted
- 15 Dec 2025
- First applicant approval
- 2 Dec 2025
- First marketing
- 28 May 2026
- Last qualifying patent expiry (as listed by FDA)
- 24 Nov 2026
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week